Omeros Corporation (NASDAQ:OMER) declared that an update on OMS824, the firm's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease: Omeros has suspended its Huntington's clinical trial as it further evaluates an observation from a nonclinical study in rats. Omeros Corporation (NASDAQ:OMER) has the market capitalization of 412.0 Million. Shares of firm plunged -12.30% to close at $12.12 with the total traded volume of 1.07 Million. The firm has current ratio of 3.20 for the most recent quarter.The Travelers Companies, Inc. (NYSE:TRV) released that its third quarter operating earnings of $2.61 a share, $0.33 improved than the Capital IQ Consensus anticipated of $2.28. Surges in book value per share of 9% to $76.42 and adjusted book value per share of 6 percent to $70.64 from year-end 2013. The Travelers Companies, Inc. (NYSE:TRV) stock price closed at $94.24 with the total traded volume of 3.5 Million shares. Its price to sales ratio ended at 1.20. Its market capitalization is 31.951 Billion. The stock owned by the Financial Institutions was 84.30% while by insiders was 0.30%.Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) declared that Dr. Anthony Lembo of Beth Israel Deaconess Medical Center will present the results of TARGET 3 in a late-breaking podium presentation at the American College of Gastroenterology meeting. In this phase, 42 percent of subjects responded based on the FDA-required composite endpoint of symptomatic relief in both abdominal pain and stool consistency. Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) begun last trade with a price of $142.93 and throughout the trading session climbed at a high of $143.51. The day-trade ended with -1.01% to $140.55. The stock is going forward to its 52 week low with 98.97% and lagging behind from its 52 week high price with -18.75%. SLXP last month stock price volatility remained 4.84%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
